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A none sedating antihistamine is the treatment of
choice for most patients with urticaria. There are,
however, several occasions where alternative treat-
ments are appropriate. In this paper these alternative
treatments of various types of urticaria are discussed.
The treatment of anaphylactic shock where urticaria
often is the ®rst sign is also discussed. In all types of
urticaria it is important to work with the patient and
try to eradicate the cause or inhibit the mediators
giving the clinical signs. Key words: anaphylactic shock/
antihistamines. Journal of Investigative Dermatology
Symposium Proceedings 6:157±159, 2001
ACUTE URTICARIA
In severe urticaria with intolerable itching subcutaneous injection
of epinephrine solution (in adults, 0.3±0.8 ml of a solution with
1 mg per 1 ml) has an effect after only 5 min. It is of short duration
and the nonsedating antihistaminic drug should be given simul-
taneously to block the reaction to later-released histamine.
As an alternative to the antihistamine sometimes oral cortico-
steroids can be given to otherwise healthy patients. Zuberbier et al
(1996) compared treatment with prednisolone 50 mg for 3 d with
loratadine 10 mg daily in 99 patients. Both drugs were equally
effective in controlling itching and whealing, but prednisolone
worked quicker with complete remission in 94% after 3 d,
compared with 66% of the patients treated with loratadine. The
three patients who failed to clear on prednisolone responded to
further treatment with loratadine. All patients were followed for
8 wk and none of the patients progressed to chronic urticaria. It
was pointed out that the antihistamines should be chosen when
prolonged treatment is necessary, as they have hardly any potential
adverse effects compared with corticosteroids.
URTICARIA WITH SIGNS OF ANAPHYLACTIC SHOCK
If the condition is progressing slowly and is not life threatening,
subcutaneous epinephrine, a none sedating oral antihistamine, and
4±8 mg betamethasone in water may be adequate. Airways need to
be monitored and kept free, and oxygen should be available in case
of breathing dif®culties. If bronchoconstriction occurs, inhalation
of a b2 stimulator should be given. Pulse and blood pressure should
also be monitored, and the patient should be in a supine position
with an intravenous line inserted. If signs of severe anaphylaxis with
hypotension due to vasodilation and loss of plasma occur,
immediately start infusion with saline or Ringer's acetate solution
and contact other staff members and the anesthesiologist.
Adrenaline injection subcutaneously can be repeated if needed
every 15±30 min if there are no contraindications.
To give the most ef®cient treatment it is important to have an
updated consensus list about what should be done; however, as
there is no time to stand and read it in an emergency regular and
repeated training of all personal is of utmost importance for this
threatening condition. In a recent study of management of
anaphylaxis in 20 fatal cases, those thought to be due to food
caused dif®culty in breathing that mainly led to respiratory arrest;
shock was more common in iatrogenic and venom reactions
(Pumphrey, 2000). A few reactions will be fatal whatever treatment
is given; therefore avoidance of its cause is important as previous
reactions had been overlooked in these cases. Kit for self-treatment
was unhelpful; its success depends on selection of medication, ease
of use, and good training (Pumphrey, 2000).
URTICARIA FACTITIA (DERMOGRAPHISM)
Many patients have remarked that they are better when they have
been sunbathing. Irradiation with UVB decreases the sensitivity of
the mast cells and can be an additional treatment. Because dry skin
is the cause of scratching, a lubricating cream is useful, as is avoiding
woollen clothing next to the skin. Delayed dermographism
responds poorly to antihistamines, suggesting that other mediators
also are involved. It can occur together with pressure urticaria and
might have the same pathogenesis.
PRESSURE URTICARIA
The skin lesions due to pressure do not usually respond to
antihistamines, although a concurrent chronic urticaria can be
inhibited (Sussman et al, 1982). There are, however, reports that
cetirizine can be effective (Kontou-Fili et al, 1991; Werner and
Marsch, 1992); the results could not be con®rmed by others
(KruÈger-Krasagakes and Henz, 1998). Prednisolone in daily doses
of 40 mg can have an effect but prolonged treatment is not
recommended (Sussman et al, 1982; Dover et al, 1988). Aspirin
daily also moderately suppressed the symptoms of pressure but
could aggravate the urticarial lesions. Sulfasalazine was bene®cial in
two patients (Engler et al, 1995). Dapsone 50 mg daily stopped the
symptoms in ®ve patients but they reappeared in four when
treatment was stopped. Reintroduction cleared all lesions and the
concentration could be tapered without relapse (Dayani et al, 1992).
CHOLINERGIC URTICARIA
For very severe cases danazole might be considered (Wong et al,
1987; Berth-Jones and Graham-Brown, 1989).
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ADRENERGIC URTICARIA
The disorder is the counterpart to cholinergic urticaria. Treatment
with a b-blocker like propanolol 20 mg twice daily was effective
(Shelley and Shelley, 1985).
COLD URTICARIA
Desensitization can be achieved by washing, for example, the face
with cold water every morning and evening. For larger areas it can
be a time-consuming procedure and requires close clinical
supervision (Henquet et al, 1992).
SOLAR URTICARIA
In very sensitive patients with this rare condition it is not possible to
suppress the symptoms even with potent oral antihistamines,
although the itching might disappear (Farr, 2000). Desensitizing by
daily irradiation with UVB and UVA is then often the treatment of
choice (Ryckaert and Roelands, 1998; Uetsu et al, 2000). Uetsu et al
(2000) reported that injection of autologous serum, which had been
previously irradiated at the action spectrum in vitro, caused an
urticarial wheal but not when injected in normal subjects. We
studied a patient sensitive to 290±420 nm. Intradermal injection of
his plasma was only positive to irradiated plasma (Juhlin and
Malmros-Enander, 1986). The patient was desensitized daily with
UVA for 2 wk in increasing concentrations from 1 s to 10 min
(= 9 J per cm2). Irradiation tests with different wavelengths were
now negative and the patient could be out in the sun for hours
without any problems; however, daily treatments were needed.
Improvement after removing the plasma factor by plasmapheresis
has been reported. Collins et al (1996) reviewed the patients treated.
Remission was reported in four patients for 2 wk to 4 y, whereas
four patients showed no improvement. Cyclosporin A (4.5 mg per
kg per d) decreased the photosensitivity in one patient studied by
EdstroÈm and Ros (1997). The symptoms returned, however, 1±
2 wk after the treatment was stopped. Protective sunscreens can
have an effect in patients where the sensitivity is limited to the
shorter wavelengths.
URTICARIA PIGMENTOSA
PUVA treatment can decrease the symptoms of both diffuse and
solitary mastocytosis for 3±12 mo, but the effect does not appear to
be related to any marked change in mast cell numbers (Christophers
et al, 1978; Vella Briffa et al, 1983; Czarnetzki et al, 1985). Topical
application of potent corticosteroids under occlusion or local
injection induced almost complete clearing with disappearance of
mast cells and decrease of local histamine levels (Barton et al, 1985).
The treated areas remained improved for 9±12 mo. Similar clinical
effects were noted when the corticosteroids were applied under a
hydrocolloid dressing (Taylor et al, 1993).
Disodium chromoglycate can improve the gastrointestinal
symptoms in patients with systemic mastocytosis (Czarnetzki and
Behrendt, 1981; Soter et al, 1981; Horan et al, 1990). Interferon a
has been found to be effective in two patients and in others it could
control the symptoms but had no in¯uence on the cutaneous
lesions (Kolde et al, 1995). A combination of interferon a with
corticosteroids improved the systemic disease but the side-effects
limit its use (Delaporte et al, 1995).
CHRONIC URTICARIA
UVB and UVA treatment for 1±3 mo has been effective in many
patients (Hannuksela and Kokkunen, 1985; Olafsson et al, 1986).
Clinical trials with combined H1 and H2 blockers in chronic
urticaria have produced con¯icting results (Kennard and Ellis,
1991; Juhlin and Landor, 1993). My own experience is that a
combination has a limited role in chronic urticaria. A moderate
increase of the H1 antihistamine mostly gives the same effect.
When the H1 antihistamines have no effect the addition of a
corticosteroid is usually effective. It is important to determine the
lowest possible concentration. We usually start with 40 mg
prednisolone for 2 d and decrease the concentration by 10 mg
daily for 3 d and then use an alternate-day regimen for another
2 wk. Recurrence is common but if the response is dramatic 5±
10 mg of prednisolone can be reinstituted for a week during severe
exacerbations. Prolonged corticosteroid treatment should generally
not be given for chronic urticaria; it can, however, be used in
urticarial vasculitis and then often in combination with colchicine
or dapsone (Callen and Kalb¯eisch, 1982; Werni et al, 1986).
Sulfasalazine has also been used in corticosteroid-dependent
chronic urticaria (Jaffer, 1991). Cyclosporin up to 5 mg per kg
has been proven effective in patients with severe chronic urticaria
(Fradin et al, 1991; Barlow et al, 1993; Toubi et al, 1997; Vena et al,
2000). Therapy withdrawal is often followed by recurrences and
the possible side-effects limit its use.
Evident or occult bacterial, viral, fungal, and parasitic infections
have been implicated as possible causes of both acute and chronic
urticaria (Shelley and Shelley, 1987; Henz and Zuberbier, 1998).
Resolution of the urticaria after treatment has been reported. A
yeast-free diet in combination with nystatin for a week can decrease
the symptoms (MoÈller et al, 1995). Eradication of Helicobacter pylori
in chronic urticaria was reported as very bene®cial by several
authors (Wedi et al, 1998). Later studies, however, indicated that
the eradication does not appear to in¯uence the symptoms
(Ozkaya-Bayazit et al, 1998; Valsecchi and Pigatto, 1998;
Schnyder et al, 1999).
For severe unremitting urticaria plasmapheresis could in some
patients abolish the symptoms for some weeks and the reaction to
autologous sera was decreased compared with sera taken before the
procedure (Grattan et al, 1992). Speci®c histamine releasing
antibodies have now been found in 25%±45% of patients with
chronic urticaria. The positive autologous serum skin test is more
common in patients where such antibodies had been found (Sabroe
et al, 1999). Intravenous immunoglobulin, which is a polyvalent
antibody from healthy donors, caused a complete remission of
urticaria in three patients, a temporary remission in two, and a
partial improvement in the remaining ®ve (O'Donnell et al, 1998).
Autologous intradermal tests with post-treatment sera showed a
reduced wheal and ¯are. In our studies with intradermal autologous
serum and plasma the erythematous in®ltrate reached its maximum
after 5±24 h, as was seen after injection of kallikrein (Juhlin and
MichaeÈlsson, 1969a). One patient also reacted to tests with serum
from two patients with hereditary angiedema lacking Cl esterase
inhibitor, but not to tests with sera from a healthy subject with the
same blood group. A signi®cantly increased immediate and delayed
test to kallikrein was found in chronic urticaria and hereditary
angiedema, but not in other types of urticaria. We therefore
believed that the reactions to serum could be due to a lack of
kallikrein inhibitors, especially as the urticaria and reactions could
be inhibited by the trypsin and kallikrein inhibitor, aprotinin
(Trasylol) (Juhlin and MichaeÈlsson, 1969b). Unfortunately the risk
for anaphylactic reaction limited the usefulness of this drug.
Heparin and warfarin have been reported to inhibit urticaria
(Meyer de Schmidt and Neuman, 1952; Duvall et al, 1986; Berth-
Jones et al, 1988). We could con®rm this in patients who received
the drugs for other indications. The response of chronic urticaria to
warfarin was recently established in a double-blind study (Parslew
et al, 2000).
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